The Significance of Long Noncoding RNA H19 in Predicting Progression and Metastasis of Cancers: A Meta-Analysis

Recently, numerous studies indicate that H19 plays a key role in tumorigenesis, but the results have been disputed, especially in the aspects of tumor progression and metastasis. Therefore, we performed this meta-analysis to systematically summarize the relationship between H19 and cancers. We searched PubMed, the Cochrane Library, CNKI, and Chinese Wan Fang to identify eligible studies. Odds ratios and 95% confidence intervals were calculated to assess the effect size. A total of 13 studies were enrolled in this meta-analysis, which was performed by Revman5.3 and Stata11.0 software. Our meta-analysis showed that the expression of H19 was associated with distant metastasis in nongastrointestinal tumors (OR = 3.85, 95% CI = 1.31–11.36,P=0.01) and, in gastrointestinal tumors (OR = 0.34, 95% CI = 0.15–0.78,P=0.01), lymph node metastasis (OR = 2.04, 95% CI = 1.19–3.48,P=0.009). Moreover, in gastric cancer, H19 expression was significantly related to histological grade (OR = 0.50, 95% CI = 0.29–0.86,P=0.01), TNM stage (OR = 0.19, 95% CI = 0.11–0.33,P<0.01), and tumor invasion depth (OR = 0.11, 95% CI = 0.04–0.27,P<0.01). Therefore, H19 could serve as a potential marker for progression and metastasis evaluation of cancers.

Download Full-text

Appendectomy Does Not Increase the Risk of Future Emergence of Parkinson’s Disease: A Meta-analysis

The American Surgeon ◽

10.1177/0003134821989034 ◽

2021 ◽

pp. 000313482198903

Author(s):

Mitsuru Ishizuka ◽

Norisuke Shibuya ◽

Kazutoshi Takagi ◽

Hiroyuki Hachiya ◽

Kazuma Tago ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Meta Analysis ◽

Cochrane Library ◽

Random Effects Models ◽

Significant Difference ◽

The Cochrane Library ◽

The Impact ◽

The Relationship ◽

Observation Period

Objective To explore the impact of appendectomy history on emergence of Parkinson’s disease (PD). Background Although there are several studies to investigate the relationship between appendectomy history and emergence of PD, the results are still controversial. Methods We performed a comprehensive electronic search of the literature (the Cochrane Library, PubMed, and the Web of Science) up to April 2020 to identify studies that had employed databases allowing comparison of emergence of PD between patients with and those without appendectomy history. To integrate the impact of appendectomy history on emergence of PD, a meta-analysis was performed using random-effects models to calculate the risk ratio (RR) and 95% confidence interval (CI) for the selected studies, and heterogeneity was analyzed using I2 statistics. Results Four studies involving a total of 6 080 710 patients were included in this meta-analysis. Among 1 470 613 patients with appendectomy history, 1845 (.13%) had emergences of PD during the observation period, whereas among 4 610 097 patients without appendectomy history, 6743 (.15%) had emergences of PD during the observation period. These results revealed that patients with appendectomy history and without appendectomy had almost the same emergence of PD (RR, 1.02; 95% CI, .87-1.20; P = .83; I2 = 87%). Conclusion This meta-analysis has demonstrated that there was no significant difference in emergence of PD between patients with and those without appendectomy history.

Download Full-text

Resting Heart Rate as a Predictor of Cancer Mortality: A Systematic Review and Meta-Analysis

Journal of Clinical Medicine ◽

10.3390/jcm10071354 ◽

2021 ◽

Vol 10 (7) ◽

pp. 1354

Author(s):

Diana P. Pozuelo-Carrascosa ◽

Iván Cavero-Redondo ◽

I.M. Lee ◽

Celia Álvarez-Bueno ◽

Sara Reina-Gutierrez ◽

...

Keyword(s):

Heart Rate ◽

Cancer Mortality ◽

Meta Analysis ◽

Positive Association ◽

Cochrane Library ◽

Resting Heart Rate ◽

Potential Marker ◽

Meta Analyses ◽

Risk Of Cancer ◽

The Relationship

This work was aimed to synthetize the evidence available about the relationship between resting heart rate (RHR) and the risk of cancer mortality. A computerized search in the Medline, EMBASE, Web of Science, and Cochrane Library databases from their inception to 24 September 2020 was performed. We performed three meta-analyses: (1) cancer mortality comparing the “less than 60 bpm” and “more than 60 bpm” categories; (2) cancer mortality comparing “less than 60 bpm”, “60 to 80 bpm”, and “more than 80 bpm” categories; and (3) analysis for 10–12 and 20 bpm increase in RHR and risk of cancer mortality. Twenty-two studies were included in the qualitative review, and twelve of them met the inclusion criteria for the meta-analysis. Our results showed a positive association between RHR and the risk of cancer mortality. This association was shown in a meta-analysis comparing studies reporting mean RHR values below and above 60 bpm, when comparing three RHR categories using less than 60 bpm as the reference category and, finally, in dose response analyses estimating the effect of an increase of 10–12 bpm in RHR, both in men and in women. In conclusion, a low RHR is a potential marker of low risk of cancer mortality.

Download Full-text

Effect of Statins on the Risk of Different Stages of Prostate Cancer: A Meta-Analysis

Urologia Internationalis ◽

10.1159/000518164 ◽

2021 ◽

pp. 1-9

Author(s):

Yun Li ◽

Xuan Cheng ◽

Jia-lian Zhu ◽

Wen-wen Luo ◽

Huai-rong Xiang ◽

...

Keyword(s):

Prostate Cancer ◽

Lower Risk ◽

Advanced Prostate Cancer ◽

Meta Analysis ◽

Cochrane Library ◽

Low Grade ◽

High Grade ◽

The Cochrane Library ◽

The Relationship ◽

Comprehensive Literature Search

Introduction: The aim of this article was to investigate the relationship between statins and the risk of different stages or grades of prostate cancer. Methods: A comprehensive literature search was performed for articles published until December 18, 2020, on the PubMed, Embase, and the Cochrane Library databases. The pooled relative risk (RR) and 95% confidence interval (CI) were then analyzed using the STATA.16.0 software. Results: A total of 588,055 patients from 14 studies were included in the analysis. We found that the use of statins expressed a significant correlation with a lower risk of advanced prostate cancer (RR = 0.81, 95% CI: 0.73–0.91; RR = 0.86, 95% CI: 0.75–0.99, respectively). However, no evidence suggested that the use of statins was beneficial for the prevention of localized prostate cancer incidence. Similarly, the pooled results also revealed no association between the use of statins and the risk of high-grade and low-grade prostate cancer. Conclusion: It has been found that the use of statins is associated with a lower risk of advanced prostate cancer but was not related to the risk of localized, low-grade, or high-grade prostate cancer.

Download Full-text

Influence of NQO1 Polymorphisms on Warfarin Maintenance Dose: A Systematic Review and Meta-Analysis (rs1800566 and rs10517)

Cardiovascular Therapeutics ◽

10.1155/2021/5534946 ◽

2021 ◽

Vol 2021 ◽

pp. 1-9

Author(s):

Lihong Tian ◽

Pingping Xiao ◽

Bingrong Zhou ◽

Yishan Chen ◽

Lijuan Kang ◽

...

Keyword(s):

Maintenance Dose ◽

Meta Analysis ◽

Warfarin Dose ◽

Maintenance Dosage ◽

Sensitivity Analyses ◽

Cochrane Library ◽

The Cochrane Library ◽

The Relationship ◽

Review Manager ◽

Warfarin Maintenance Dose

This meta-analysis was conducted to analyze the effect of NQO1 polymorphism on the warfarin maintenance dosage. Using strict inclusion and exclusion criteria, we searched PubMed, EMBASE, and the Cochrane Library for eligible studies published prior to July 7, 2021. The required data were extracted, and experts were consulted when necessary. Review Manager Version 5.4 software was used to analyze the relationship between NQO1 polymorphisms and the warfarin maintenance dosage. Four articles involving 757 patients were included in the meta-analysis. Patients who were NQO1 rs10517 G carriers (AG carriers or GG carriers) required a 48% higher warfarin maintenance dose than those who were AA carriers. Patients with NQO1 rs1800566 CT carriers required a 13% higher warfarin dose than those who were CC carriers, with no associations observed with the other comparisons of the NQO1 rs1800566 genotypes. However, the results obtained by comparing the NQO1 rs1800566 genotypes require confirmation, as significant changes in the results were found in sensitivity analyses. Our meta-analysis suggests that the NQO1 rs10517and NQO1 rs1800566 variant statuses affect the required warfarin maintenance dose.

Download Full-text

Metabolic Syndrome Increases the Risk for Knee Osteoarthritis: A Meta-Analysis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2016/7242478 ◽

2016 ◽

Vol 2016 ◽

pp. 1-7 ◽

Cited By ~ 14

Author(s):

Huajun Wang ◽

Yanmei Cheng ◽

Decheng Shao ◽

Junyuan Chen ◽

Yuan Sang ◽

...

Keyword(s):

Metabolic Syndrome ◽

Knee Osteoarthritis ◽

Meta Analysis ◽

Cochrane Library ◽

Significant Heterogeneity ◽

Metabolic Factors ◽

Knee Oa ◽

The Metabolic Syndrome ◽

The Cochrane Library ◽

The Relationship

Background. Studies revealed that metabolic factors might contribute substantially to osteoarthritis (OA) pathogenesis. There has been an increasing interest to understand the relationship between knee OA and the metabolic syndrome (MetS). The purpose of this study was to explore the association between metabolic syndrome and knee osteoarthritis using meta-analysis.Methods. Databases, including PUBMED, EMBASE, and the Cochrane Library, were searched to get relevant studies. Data were extracted separately by two authors and pooled odds ratio (OR) with 95% confidence interval (CI) was calculated.Results. The meta-analysis was finished with 8 studies with a total of 3202 cases and 20968 controls finally retrieved from the database search. The crude pooled OR is 2.24 (95% CI = 1.38–3.64). Although there was significant heterogeneity among these studies, which was largely accounted for by a single study, the increase in risk was still significant after exclusion of that study. The pooled adjusted OR remained significant with pooled adjusted OR 1.05 (95% CI = 1.03–1.07,p<0.00001). No publication bias was found in the present meta-analysis.Conclusions. The synthesis of available evidence supports that metabolic syndrome increases the risk for knee osteoarthritis, even after adjustment for many risk factors.

Download Full-text

The Prognostic Value of Early Repolarization Pattern for the Ventricular Tachyarrhythmias of Acute Myocardial Infarction Patients: A Meta-Analysis

Cardiology ◽

10.1159/000501474 ◽

2019 ◽

Vol 144 (3-4) ◽

pp. 69-75

Author(s):

Shangbo Xu ◽

Lihua Yang ◽

Danhua Hong ◽

Lan Chen ◽

Xin Wang

Keyword(s):

Myocardial Infarction ◽

Acute Myocardial Infarction ◽

Prognostic Value ◽

Meta Analysis ◽

Cochrane Library ◽

Ventricular Tachyarrhythmias ◽

Early Repolarization ◽

The Cochrane Library ◽

The Relationship

Several studies have indicated that early repolarization (ER) is a risk factor for ventricular tachyarrhythmias (VTAs) in acute myocardial infarction (AMI) patients. The prognostic values of ER detail characteristics except J-point morphology, and inferior leads ER location for VTAs are still unclear. We searched PubMed, Embase, and the Cochrane Library for eligible studies up to March 4, 2019. Studies to investigate the relationship between ER and the incidence of VTAs in AMI patients were extracted. A total of 10 studies with 2,672 participants were included in the analysis. ER significantly predicted the incidence of VTAs (odds ratio [OR] 3.62, 95% confidence intervals [CI] 2.77–4.73), regardless of the type of AMI. The presence of ER before AMI (OR 5.58, 95% CI 3.41 to 9.12) and after AMI (OR 3.02, 95% CI 2.19–4.15) increased the risk of VTAs. The prognostic value of ER for VTAs in the long follow-up (≥30 days) (OR 2.39, 95% CI 1.59–3.59) fell by half compared to the short follow-up duration (<30 days) (OR 4.97, 95% CI 3.48–7.09). Patients with ER displayed a higher risk of developing ventricular fibrillation (VF) (OR 6.94, 95% CI 3.87–12.43) than those without ER. However, neither J-point elevation with OR = 2.48 nor lateral leads’ ER location with OR = 3.83 remarkably increased the risk of VTAs in patients with AMI. ER is significantly associated with increasing risk of VTAs, particularly VF, in AMI patients. This relationship is weaker in the 30-day follow-up and is not reinforced by J-point elevation and lateral leads’ ER location.

Download Full-text

The relationship between Fas and Fas ligand gene polymorphism and preeclampsia risk

Bioscience Reports ◽

10.1042/bsr20181901 ◽

2019 ◽

Vol 39 (2) ◽

Cited By ~ 1

Author(s):

Tingting Wang ◽

Yunyun Lian

Keyword(s):

Fas Ligand ◽

Meta Analysis ◽

Cochrane Library ◽

Nucleotide Polymorphisms ◽

Multisystem Disorder ◽

Increased Risk ◽

Fasl Gene ◽

The Cochrane Library ◽

The Relationship ◽

Risk Of Preeclampsia

Abstract Preeclampsia is an idiopathic multisystem disorder with partial genetic and immunological etiology. Several studies investigated the association between various single-nucleotide polymorphisms (SNPs) in Fas and Fas ligand (FasL) genes and the risk of preeclampsia. However, they achieved inconsistent results. Therefore, we conducted a meta-analysis by systematically searching the Cochrane Library, PubMed and Embase databases and assessed this association by calculating pooled odds ratios with 95% confidence interval to reach a more trustworthy conclusion. Subgroup analyses by genotype methods and source of controls (SOC) were also conducted. Seven citations containing nine studies were included for four SNPs (Fas -670 A/G, FasL 124A/G, FasL -844C/T, Fas -1377 G/A) in this meta-analysis. Our data suggested the G allele and genotype GG of the Fas -670 A/G polymorphism, GG genotype of the FasL 124A/G polymorphism, and TT genotype of the FasL -844C/T polymorphism increased the risk of preeclampsia. Stratification analyses by genotype methods and SOC also indicated that Fas -670 A/G polymorphism was related to increased risk for preeclampsia. In conclusion, Fas and FasL gene polymorphisms play important roles in the development of preeclampsia. Further well-designed studies in other races are needed to confirm the findings of this meta-analysis.

Download Full-text

Clinicopathological and Prognostic Value of SNHG6 in Cancers: a Systematic Review and a Meta-analysis

10.21203/rs.2.21436/v1 ◽

2020 ◽

Author(s):

Shuo Zhang ◽

Dandan Qiu ◽

Xiaohong Xie ◽

Yong Shen

Keyword(s):

Tumor Invasion ◽

Prognostic Value ◽

Meta Analysis ◽

Tnm Stage ◽

Invasion Depth ◽

Clinical Value ◽

Human Cancers ◽

Hazard Ratios ◽

Non Coding Rna ◽

Tumor Invasion Depth

Abstract Background: The long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) is dysregulated in various malignant tumor. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers.Methods: A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage. Results: A total of 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56~2.52) with no heterogeneity (I2 = 0.0%, p = 0.996). Subgroup analysis indicated a significant association between high SNHG6 expression and shorter OS in studies with digestive system cancers (HR = 2.05, 95%CI: 1.47-2.62), sample size < 70 (HR = 2.70, 95%CI: 1.29-4.11), and univariate and multivariate analysis (HR = 2.04, 95%CI: 1.44-2.64). Moreover, high SNHG6 expression was positively correlated with tumor invasion depth (OR = 1.76, 95%CI: 1.18-2.63), LNM (OR = 1.60, 95%CI: 1.18-2.17), DM (OR = 1.90, 95%CI: 1.37-2.64) and advanced TNM stage (OR = 1.88, 95%CI: 1.36-2.60) in patients with cancers.Conclusions: High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.

Download Full-text

Association between PTEN and clinical-pathological features of osteosarcoma

Bioscience Reports ◽

10.1042/bsr20190954 ◽

2019 ◽

Vol 39 (7) ◽

Cited By ~ 5

Author(s):

Jian Zhou ◽

Xia Xiao ◽

Wanchun Wang ◽

Yingquan Luo

Keyword(s):

Meta Analysis ◽

Clinicopathological Features ◽

Pten Expression ◽

Cochrane Library ◽

Medical Database ◽

Phosphatase And Tensin Homolog ◽

Tensin Homolog ◽

Positive Expression ◽

The Cochrane Library ◽

The Relationship

Abstract Previous studies indicated the prognostic value of phosphatase and tensin homolog deleted on chromosome ten (PTEN) in osteosarcoma (OS). There was a great degree of inconsistency between these reports. The aim of this meta-analysis was to investigate the clinicopathological features and prognostic role of PTEN positive expression on OS. We searched NCBI PubMed, Embase, Springer, ISI Web of Knowledge, the Cochrane library, China National Knowledge Internet database (CNKI), Wanfang database, Chinese VIP database and Chinese Biological Medical Database (CBM) for relevant papers published before 28 November 2018. The eligibility of all retrieved studies assessing the relationship between PTEN expression and clinicopathological and prognostic outcomes in OS were incorporated. Pooled odds ratio (OR) and 95% confidence intervals (CIs) were used to estimate the outcomes. A total of 13 studies with 580 OS patients were involved to assess the relationship between PTEN expression and clinicopathological features of OS. PTEN positive expression was significantly associated with male (OR = 1.57, 95% CI: 1.03–2.38, P=0.035<0.05) and OS high differentiation (OR = 2.33, 95% CI: 1.26–4.29, P=0.007<0.05). Additionally, positive expressions of PTEN predict no neoplasm metastasis (OR = 5.69, 95% CI: 3.64–8.90, P<0.05). The results of our study showed that positive expression of PTEN may predict higher 5-year survival in OS with the pooled OR of 8.73 (95% CI: 4.18–18.24, P<0.05). The results from the present study suggest that positive expression of PTEN is significantly associated with male, high differentiation, no metastasis and high 5-year overall survival rate in OS.

Download Full-text

Clinicopathological and Prognostic Value of SNHG6 in Cancers: a Systematic Review and a Meta-analysis

10.21203/rs.2.21436/v2 ◽

2020 ◽

Author(s):

Shuo Zhang ◽

Dandan Qiu ◽

Xiaohong Xie ◽

Yong Shen

Keyword(s):

Tumor Invasion ◽

Prognostic Value ◽

Meta Analysis ◽

Tnm Stage ◽

Invasion Depth ◽

Clinical Value ◽

Human Cancers ◽

Hazard Ratios ◽

Non Coding Rna ◽

Tumor Invasion Depth

Abstract Background The long non-coding RNA small nucleolar RNA host gene 16 (lncRNA SNHG6) is dysregulated in various malignant tumor. However, a definite conclusion on the clinical value of lncRNA SNHG6 expression in human cancers has not been determined. The purpose of the present meta-analysis was to comprehensively elucidate the association between SNHG6 expression and clinical outcomes in cancers. Methods A systematic search was performed through the PubMed, Web of Science, Chinese National Knowledge Infrastructure (CNKI), and Wangfang databases for relevant studies. The pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were collected to estimate the prognostic value, and the odds ratios (ORs) with 95% CIs were used to evaluate the relationship between lncRNA SNHG6 expression and clinicopathological features, including tumor invasion depth, lymph node metastasis (LNM), distance metastasis (DM), and TNM stage. Results A total of 914 patients from 13 studies were included in this meta-analysis. The pooled results suggested that evaluated SNHG6 expression could predict an unfavorable overall survival (OS) (HR = 2.04, 95% CI:1.56~2.52) with no heterogeneity ( I 2 = 0.0%, p = 0.996). Subgroup analysis indicated a significant association between high SNHG6 expression and shorter OS in studies with digestive system cancers (HR = 2.05, 95%CI: 1.47-2.62), sample size < 70 (HR = 2.70, 95%CI: 1.29-4.11), and univariate and multivariate analysis (HR = 2.04, 95%CI: 1.44-2.64). Moreover, high SNHG6 expression was positively correlated with tumor invasion depth (OR = 1.76, 95%CI: 1.18-2.63), LNM (OR = 1.60, 95%CI: 1.18-2.17), DM (OR = 1.90, 95%CI: 1.37-2.64) and advanced TNM stage (OR = 1.88, 95%CI: 1.36-2.60) in patients with cancers. Conclusions High lncRNA SNHG6 expression was correlated with tumor invasion depth, LNM, DM, and advanced TNM stage, suggesting that SNHG6 may serve as a promising prognostic biomarker of human cancers.

Download Full-text